Cue Biopharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
40 GUEST STREET, BOSTON, MA, 02135
Mailing Address
40 GUEST STREET, BOSTON, MA, 02135
Phone
617-949-2680
Fiscal Year End
1231
EIN
473324577
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 16, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 16, 2026 | View on SEC |
| 10-K Annual financial report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Secured a major licensing partnership with Boehringer Ingelheim for CUE-501, including a $15 million upfront payment and potential milestones exceeding $400 million.
- Significantly reduced net loss in 2023 to $59.2 million from $69.8 million in 2022, primarily driven by collaboration revenue.
Material Events
8-K
Leadership Change
March 27, 2026
High Impact
- Appointment of Lucinda Warren as Interim CEO, leveraging her 25-year J&J background.
- Strategic pivot toward business development, potential asset sales, and partnership opportunities.
8-K
Strategy Change
March 16, 2026
High Impact
- Achieved an unexpected net profit of $1.585 million in Q4 2025, reversing a $9.5 million loss from Q4 2024.
- Collaboration revenue skyrocketed to $21.9 million in Q4 2025 due to a new strategic partnership with ImmunoScape.
Insider Trading
BUY
1 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.